Interim 2023/2024 Season Influenza Vaccine Effectiveness in Primary and Secondary Care in the United Kingdom

Influenza Other Respir Viruses. 2024 May;18(5):e13284. doi: 10.1111/irv.13284.

Abstract

Background: We report 2023/2024 season interim influenza vaccine effectiveness for three studies, namely, primary care in Great Britain, hospital settings in Scotland and hospital settings in England.

Methods: A test negative design was used to estimate vaccine effectiveness.

Results: Estimated vaccine effectiveness against all influenzas ranged from 63% (95% confidence interval 46 to 75%) to 65% (41 to 79%) among children aged 2-17, from 36% (20 to 49%) to 55% (43 to 65%) among adults 18-64 and from 40% (29 to 50%) to 55% (32 to 70%) among adults aged 65 and over.

Conclusions: During a period of co-circulation of influenza A(H1N1)pdm09 and A(H3N2) in the United Kingdom, evidence for effectiveness of the influenza vaccine in both children and adults was found.

Keywords: effectiveness; hospitalisation; influenza; vaccine.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Influenza A Virus, H1N1 Subtype* / immunology
  • Influenza A Virus, H3N2 Subtype* / genetics
  • Influenza A Virus, H3N2 Subtype* / immunology
  • Influenza Vaccines* / administration & dosage
  • Influenza Vaccines* / immunology
  • Influenza, Human* / epidemiology
  • Influenza, Human* / prevention & control
  • Male
  • Middle Aged
  • Primary Health Care*
  • Seasons
  • Secondary Care*
  • United Kingdom
  • Vaccination / statistics & numerical data
  • Vaccine Efficacy
  • Young Adult